New discovery programmes, trial questions and dementia diagnostics

1. FDA asks for evidence to guide early ibogaine trials¹

The FDA opened a request for information on 5 October about designing early-phase trials of ibogaine products. It seeks evidence on patient selection, dose escalation, care settings, stopping rules and independent safety oversight, including monitoring for cardiac and neurological adverse events. The agency says responses could inform drug-development approaches; this is a consultation, not an approval or evidence that ibogaine works. For pharmacology researchers, it identifies concrete protocol questions requiring data before potential benefits can be judged. The announced comment deadline is 20 November 2026.¹

2. Iambic submits an application to begin IAM217 clinical testing²

Iambic announced on 5 October that it had submitted an Investigational New Drug application for IAM217, a KIF18A inhibitor intended for cancers with chromosomal instability. The company plans a Phase 1/2 trial, subject to FDA clearance. It says its AI tools and automated chemistry helped optimise the molecule, including properties intended to support brain penetration. Those claims describe the company’s development work and preclinical observations, not demonstrated benefit in patients. The submission is a concrete milestone for an AI-assisted discovery programme; it does not mean the regulator has authorised the trial.²

3. Gate and Lilly expand molecular-gate discovery into another target³

Gate Bioscience announced an expanded collaboration with Lilly on 5 October, adding one target and an option for a second to their existing molecular-gate programme. Gate will lead discovery; Lilly will handle later preclinical work, clinical development, manufacturing and commercialisation. The approach aims to eliminate selected disease-related proteins by blocking their passage through the Sec61 secretory channel. Gate describes an expansion into another therapeutic area, giving this small-molecule strategy additional development scope. Potential agreement value could exceed $870 million, contingent on milestones; that figure is not an upfront payment or evidence of clinical success.³

4. Medicine Nobel recognises light-controlled tools for studying nerve cells⁴

The 2026 Nobel Prize in Physiology or Medicine recognises Peter Hegemann, Georg Nagel and Karl Deisseroth for the discoveries behind optogenetics, Karolinska Institutet announced on 5 October. Hegemann and Nagel identified light-sensitive channelrhodopsin in algae; Deisseroth developed its use to control nerve-cell activity. The approach allows researchers to perturb selected neural circuits and test their contribution to behaviour and disease-related processes. For pharmacology readers, the award highlights a widely used experimental route from molecular control to functional mechanisms. It celebrates an established research capability, rather than announcing a newly proven drug treatment.⁴

5. UK programme will test dementia biomarkers in NHS services⁵

UK Research and Innovation announced nine dementia-diagnosis projects on 2 October within a challenge backed by up to £80 million. The portfolio includes introducing a blood-biomarker panel into routine NHS memory services, an AI decision tool using clinical records and blood tests, and Scottish living labs for biomarkers and treatments. Projects will undergo real-world testing, with further funding dependent on demonstrated progress. For molecular-diagnostics researchers, the programme creates a route from analytical validation to testing in clinical workflows. The announcement establishes funded implementation work; it does not show that the programme has already improved diagnosis or patient outcomes.⁵